Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma

Autores: Espinet, B.; Salaverria, I.; Beà, S.; Ruiz-Xivillé, N.; Balaqué, O.; Salido, M.; Costa, D.; Carreras, J.; Rodríguez-Vicente, A. E.; García, J. L.; Hernández-Rivas, J. M.; Calasanz Abinzano, María José; Siebert, R.; Ferrer, A.; Salar, A.; Carrió, A.; Polo, N.; García-Marco, J. A.; Domingo, A.; González-Barca, E.; Romagosa, V.; Marugán, I.; López-Guillermo, A.; Millá, F.; Mate, J. L.; Luño, E.; Sanzo, C.; Collado, R.; Oliver, I.; Monzó, S.; Palacín, A.; González, T.; Sant, F.; Salinas, R.; Ardanaz, M. T.; Font, L.; Escoda, L.; Florensa, L.; Serrano, S.; Campo, E.; Solé, F.
ISSN: 1045-2257
Volumen: 49
Número: 5
Páginas: 439 - 451
Fecha de publicación: 2010
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with an aggressive behavior, characterized by the t(11;14)(q13;q32). Several secondary genetic abnormalities with a potential role in the oncogenic process have been described. Studies of large MCL series using conventional cytogenetics, and correlating with proliferation and survival, are scarce. We selected 145 MCL cases at diagnosis, displaying an aberrant karyotype, from centers belonging to the Spanish Cooperative Group for Hematological Cytogenetics. Histological subtype, proliferative index and survival data were ascertained. Combined cytogenetic and molecular analyses detected CCNDI translocations in all cases, mostly t(I I;14)(q13;q32). Secondary aberrations were present in 58% of patients, the most frequent being deletions of 1p, 13q and 17p, 10p alterations and 3q gains. The most recurrent breakpoints were identified at I p31-32, I p21-22, 17p13, and 1p36. Aggressive blastoid/pleomorphic variants displayed a higher karyotypic complexity, a higher frequency of I p and 17p deletions and 10p alterations, a higher proliferation index and poor survival. Gains of 3q and 13q and 17p 13 losses were associated with reduced survival times. Interestingly, gains of 3q and 17p losses added prognostic significance to the morphology in a multi-variate analysis. Our findings confirm previous observations indicating that proliferation index, morphology and several secondary genetic alterations (3q gains and 13q and 17p losses) have prognostic value in patients with MCL. Additionally, we observed that 3q gains and 17p losses detected by conventional cytogenetics are proliferation-independent prognostic markers indicating poor outcome.